TAGline

Volume 11 Issue 8 August 2004 en espaol C o n t e n t s #1 Statin Strength #2 TDM, Stat! More Mixes Nixed By Concentration Preoccupations #3 French Researchers Question Benefit of Lifelong Antiretroviral Treatment #4 Treatment Advocates Strategize At TAG's 2nd Annual International TB/HIV Workshop #1 Statin Strength R

Holding Court: Activist Meeting with FDA Drugs Division Sets Broad Agenda for Change; Heart of the Matter: To Date, Global Fund Offers Hype and Hope, but Little Else, to Majority of Those in Need; Écheselos, Carlton: Consejos y Prerrogativas Por Y Para El Paciente Problemático E Impenitente

XI IRTT: Why the Tap ‘n Drainers Have Always Been Wrong - Plus, A New Theory About MDR HIV; Truvánadu: Does Gilead's Famed 903 Study Really Show You What They Tell You It Shows?; Dogs and Ponies: Mixed Results (and Lots of Diarrhea) for the Tipranavir Studies - Plus Salvage Study Designs for JNJ/Tibotec's PI and Non-nuke

Little Leaps: Gilead 2-in-1 Opens Door To Impending One Pill Triple Combo; Treble Damages: Vaccine Scientists Struggle to Come to Grips with the Field's "Berlin"; Note to Hispanophone readers

Prescription for Profits: Veteran NEJM Editor Takes on Big Pharma As No One Before - Calls for Sweeping Reforms; The Agony of Bangkok: Thai Activist Exhorts Conference Crowd to Stand Firm Against US Patent Regime and 'Masks of Fake Concern'; TDM, ¡Stat!: Más Mezclas Rechazadas Debido A Preocupaciones Por Concentración

Checkmate: French African Study Offers New Challenge To Generics Obstructionists; One Step Forward: Merck Vaccine Moves Forward With Efficacy Trial, While Special Committee Tries to Salvage Thai Study; A Dios, Gracie!: Una Sutil Farmacocinética del Tipranavir Puede Confinar Su Utilización A Un Papel Limitado De Rescate

Public Unhealth: Expert Panels Decision To Recommend Against Routine HCV Screening Draws Community Ire; Goodnight, Gracie!: Quirky PK of B-I's Tipranavir May Confine Its Use to Limited Rescue Role; La Confianza Hecha Añicos: Las Decisiones de Precio de ABT, Trimeris/Roche Reavivan Viejas Preguntas Acerca de Los Costos R&D

Abbott, Trimeris/'; Roche Pricing Decisions Rekindle Old R&D Cost Questions: A generic RTV on the horizon; El Torpe Lanzamiento De T-20 Reclama Sus Primeras Víctimas, Mientras Que Las Pérdidas Se Extienden: La maldición del 'finalizador temprano'; Little Noticed Ban of Little Used Drug Triggers Little Known Investigation: Whither the checks and balances?

XI CROI, Stage For Results of Three Large HCV Treatment Trials: Still no head-to-head; La Lancha de T-20 Embrujada Llama Sus Primeras Victimas, Mientras Las Perdidas Se Despliegan: Maldicion del 'terminador temprano'; Vicissitudes of Medicine and Marketing Take Toll on Me-Too Line Up: B-I the new salvage outfit?

One Shot Immune Based Therapy Would Be Patient Dream—And Pharma's Dread: When markets fail; Frente Todas Probabilidades, Las Terapias de Base Inmune Contra el VIH Se Adelantan: 'Las dudas industriales'; Bungled T-20 Launch Claims Its First Casualties, As Losses Spread: Curse of the 'early terminator'

Proliferation of Polymerase Inhibitors and Others Tales from the HCV Crypt: Building a better ribavirin; El Fondo Global Y El Acceso A Tratamiento En Latinoamerica: Un Comentario; Against the Odds, Immune-Based Therapies for HIV Slog Along: Industry 'leery'